Johnson & Johnson, a global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations, wishes to identify druggable targets in progressive fibrosing interstitial lung disease (PF‑ILD), idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).
Research Interests
1. IPF/PF-ILDs
- Opportunities that offer the potential for clinical translation
- Mechanism of actions that reduce fibrosis by targeting TGF‑b signalling without the risk of inflammation, target activation, function of ...